Skip to main content
. 2024 Jan 17;12(1):101214. doi: 10.1016/j.gendis.2024.101214

Figure 1.

Figure 1

IGF2BP1 displays a high expression level in MM patients with 1q+ and its high expression predicts poor prognosis in these patients. (A) In the MMRF CoMMpass dataset, the relationship between IGF2BP1 mRNA levels and six kinds of CAs was quantitated. (B) In MM patients with 1q+ or t(4;14), those with a higher IGF2BP1 mRNA expression level exhibited worse OS. The IGF2BP1 mRNA expression levels were not found to be prognostically important in assessing OS in MM patients with del17p. Expression levels of IGF2BP1 mRNA were not prognostically important for assessing OS in MM patients without 1q+, del17p, or t(4;14). (C) The GSE24080 dataset was used to compare the expression level between healthy donor, MGUS, SMM, and MM groups. (D) The mRNA levels of IGF2BP1 in RNA-seq data of CD138+ plasma cells from MM patients and MGUS patients in Zhongshan Hospital were analyzed. (E) Validation of IGF2BP1 mRNA expression by qRT-PCR determined that MM patients with 1q+ had significantly higher levels of IGF2BP1 mRNA. (F) By western blot assays, CD138+ plasma cells from MM patients with 1q+ expressed a higher level of IGF2BP1 protein compared with plasma cells from MM patients without 1q+. IGF2BP1, insulin-like growth factor 2 mRNA binding protein 1; MM, multiple myeloma; OS, overall survival; CAs, cytogenetic abnormalities; SMM, smoldering MM.